Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines to treat pain and other neuronal hyperexcitability disorders, to advance SiteOne’s leading asset STC-004. Lilly will lead STC-004 through phase 2 trials and commercialisation for global markets. In return, SiteOne and its shareholders could receive up to $1bn […]
